Generic Name: Modalim Brand Name(s): Generics only. No brands available.

Uses

What is modalim (ciprofibrate) used for?

Modalim is commonly used for the treatment of primary dyslipoproteinaemias, including types IIa, IIb, III and IV (hypercholesterolemia, hypertriglyceridemia, and combined forms), refractory to appropriate dietary treatment.

Dietary measures should be continued during therapy.

How should I take modalim (ciprofibrate)?

Modalim tablets are for oral administration only.

How do I store modalim (ciprofibrate)?

Modalim is best stored at room temperature away from direct light and moisture. To prevent drug damage, you should not store modalim in the bathroom or the freezer. There may be different brands of modalim that may have different storage needs. It is important to always check the product package for instructions on storage, or ask your pharmacist. For safety, you should keep all medicines away from children and pets.

You should not flush modalim down the toilet or pour them into a drain unless instructed to do so. It is important to properly discard this product when it is expired or no longer needed. Consult your pharmacist for more details about how to safely discard your product.

Precautions & warnings

What should I know before using modalim (ciprofibrate)?

Before using this drug, tell your doctor if:

  • You are pregnant or breastfeeding. This is because, while you are expecting or feeding a baby, you should only take medicines on the recommendation of a doctor.
  • You are taking any other medicines. This includes any medicines you are taking which are available to buy without a prescription, such as herbal and complementary medicines.
  • You have allergy with any of active or inactive ingredients of modalim or other medications.
  • You have any other illnesses, disorders, or medical conditions.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.

Patients should be advised to report unexplained muscle pain, tenderness or weakness immediately.

Impaired renal function and any situation of hypoalbuminaemia such as nephrotic syndrome, high alcohol intake or hypothyroidism may increase the risk of myopathy.

As with other fibrates, the risk of rhabdomyolysis and myoglobinuria may be increased if ciprofibrate is used in combination with other fibrates or HMG CoA reductase inhibitors

Use with caution in patients with impaired hepatic function.

Periodic hepatic function tests are recommended. Modalim treatment should be discontinued if significant transaminases abnormalities persist or if cholestatic liver injury is evidenced.

Secondary causes of dyslipidaemia, such as hypothyroidism, should be excluded or corrected prior to commencing any lipid lowering drug treatment.

Is it safe during pregnancy or breastfeeding?

There isn’t enough information about the safety of using this medication during pregnancy and breastfeeding. Please always consult with your doctor to weigh the potential benefits and risks before taking this medication.

Side effects

What side effects can occur from modalim (ciprofibrate)?

Some side effects may occur when using this drug, including:

  • Rashes
  • Urticaria
  • Pruritus
  • Myalgia and myopathy
  • Headache
  • Vertigo
  • Nausea
  • Vomiting
  • Diarrhea
  • Dyspepsia
  • Abdominal pain

Not everyone experiences these side effects. There may be some side effects not listed above. If you have any concerns about a side-effect, please consult your doctor or pharmacist.

Interactions

What drugs may interact with modalim (ciprofibrate)?

Modalism may interact with other drugs that you are currently taking, which can change how your drug works or increase your risk for serious side effects. To avoid any potential drug interactions, you should keep a list of all the drugs you are using (including prescription drugs, nonprescription drugs, and herbal products) and share it with your doctor and pharmacist. For your safety, do not start, stop, or change the dosage of any drugs without your doctor’s approval.

Products may interact with this drug, such as:

  • Other fibrates
  • HMG CoA reductase inhibitors
  • Oral anticoagulant therapy

Does food or alcohol interact with modalim (ciprofibrate)?

Modalim may interact with food or alcohol by altering the way the drug works or increase the risk for serious side effects. Please discuss with your doctor or pharmacist any potential food or alcohol interactions before using this drug.

What health conditions may interact with modalim (ciprofibrate)?

Modalim may interact with your health condition. This interaction may worsen your health condition or alter the way the drug works. It is important to always let your doctor and pharmacist know all the health conditions you currently have.

Dosage

The information provided is not a substitute for any medical advice. You should ALWAYS consult with your doctor or pharmacist before using modalim (ciprofibrate).

What is the dose of modalim (ciprofibrate) for an adult?

The recommended dosage is one tablet (100mg ciprofibrate) per day. This dose should not be exceeded.

What is the dose of modalim (ciprofibrate) for a child?

The dosage has not been established in pediatric patients. It may be unsafe for your child. It is always important to fully understand the safety of the drug before using. Please consult with your doctor or pharmacist for more information.

How is modalim (ciprofibrate) available?

Modalim is available in the following dosage forms and strengths:

  • Modalim tablets 100mg

What should I do in case of an emergency or overdose?

In case of an emergency or an overdose, call your local emergency services or go to your nearest emergency room.

What should I do if I miss a dose?

If you miss a dose of modalim, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and take your regular dose as scheduled. Do not take a double dose.

Hello Health Group does not provide medical advice, diagnosis or treatment.

Sources

Review Date: May 6, 2017 | Last Modified: May 6, 2017